We report here that NCX4040 (Figure 1) is effective in inhibiting the ATPase activities of both P-gp- and BCRP-expressing human tumor cells which resulted in significant reversals of resistance to both adriamycin (P-gp) and topotecan (BCRP) in MDR tumor cells. The gene discussed is PGP; the disease is neoplasm.